<SEC-DOCUMENT>0001193125-25-004080.txt : 20250110
<SEC-HEADER>0001193125-25-004080.hdr.sgml : 20250110
<ACCEPTANCE-DATETIME>20250110073022
ACCESSION NUMBER:		0001193125-25-004080
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250109
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Cost Associated with Exit or Disposal Activities
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250110
DATE AS OF CHANGE:		20250110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Intellia Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001652130
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				364785571
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37766
		FILM NUMBER:		25520419

	BUSINESS ADDRESS:	
		STREET 1:		40 ERIE STREET
		STREET 2:		SUITE 130
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		857-285-6200

	MAIL ADDRESS:	
		STREET 1:		40 ERIE STREET
		STREET 2:		SUITE 130
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d906527d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ntla="http://intelliatx.com/20250109" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-553">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-01-09_to_2025-01-09">0001652130</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="ntla-20250109.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-01-09_to_2025-01-09"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001652130</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-09</xbrli:startDate> <xbrli:endDate>2025-01-09</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-564">8-K</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-01-09_to_2025-01-09" format="ixt:datemonthdayyearen" id="ixv-565">January 9, 2025</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-566">INTELLIA THERAPEUTICS, INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-01-09_to_2025-01-09" format="ixt-sec:stateprovnameen" id="ixv-567">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-568">001-37766</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-569">36-4785571</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Commission<br/>File Number)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-570">40 Erie Street</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-571">Suite 130</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-572">Cambridge</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-01-09_to_2025-01-09" format="ixt-sec:stateprovnameen" id="ixv-573">Massachusetts</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-574">02139</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, Including Area Code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-575">(857)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-576">285-6200</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-01-09_to_2025-01-09" format="ixt-sec:boolballotbox" id="ixv-577">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-01-09_to_2025-01-09" format="ixt-sec:boolballotbox" id="ixv-578">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-01-09_to_2025-01-09" format="ixt-sec:boolballotbox" id="ixv-579">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-01-09_to_2025-01-09" format="ixt-sec:boolballotbox" id="ixv-580">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br/>on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-581">Common Stock (Par Value $0.0001)</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-582">NTLA</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-01-09_to_2025-01-09" format="ixt-sec:exchnameen" id="ixv-583">The Nasdaq Global Market</ix:nonNumeric></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (&#167; <span style="white-space:nowrap">240.12b-2</span> of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-01-09_to_2025-01-09" format="ixt-sec:boolballotbox" id="ixv-584">&#9744;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;2.02 Results of Operations and Financial Condition. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although it has not finalized its full financial results for the fourth quarter and fiscal year ended December&#160;31, 2024, Intellia Therapeutics, Inc. (the &#8220;Company&#8221;) announced on January&#160;9, 2025, that it expects to report that it had approximately $862&#160;million of cash, cash equivalents and marketable securities as of December&#160;31, 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information contained in Item 2.02 of this Form <span style="white-space:nowrap">8-K</span> is unaudited and preliminary and does not present all information necessary for an understanding of the Company&#8217;s financial condition as of December&#160;31, 2024. The audit of the Company&#8217;s consolidated financial statements for the year ended December&#160;31, 2024, is ongoing and could result in changes to the information set forth above. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The information in this Item 2.02 is being furnished herewith and shall not be deemed </span><span style="font-style:italic">&#8220;</span><span style="font-style:italic">filed</span><span style="font-style:italic">&#8221;</span><span style="font-style:italic"> for purposes of Section</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;18 of the Securities Exchange Act of 1934, as amended (the </span><span style="font-style:italic">&#8220;</span><span style="font-style:italic">Exchange Act</span><span style="font-style:italic">&#8221;</span><span style="font-style:italic">) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing</span>. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;2.05 Costs Associated with Exit or Disposal Activities. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;9, 2025, the Company announced the prioritization of its current and near-term clinical programs and a strategic restructuring to streamline its operations. These changes are expected to extend the Company&#8217;s cash runway into the first half of 2027. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with this portfolio prioritization and strategic restructuring, the Company expects to implement a net reduction of its employee headcount by approximately 27% over 2025. The Company estimates that it will incur charges of approximately $8&#160;million for severance and other employee termination-related costs, primarily in the first quarter of 2025. These costs consist primarily of cash expenditures related to severance payments. The Company estimates that the workforce reduction will be substantially completed in the first quarter of 2025. The estimate of costs that the Company expects to incur, and the timing thereof are subject to a number of assumptions and actual results may differ. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the actions described above. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;9, 2025, the Company announced that Laura Sepp-Lorenzino, Ph.D., the Company&#8217;s Executive Vice President and Chief Scientific Officer (&#8220;CSO&#8221;), will retire from the Company and that her anticipated retirement date is December&#160;31, 2025. On January&#160;9, 2025, the Company and Dr.&#160;Sepp-Lorenzino entered into a Retirement Agreement (the &#8220;Retirement Agreement&#8221;), pursuant to which, effective January&#160;13, 2025, Dr.&#160;Sepp-Lorenzino will become Special Advisor to the Chief Executive Officer of the Company. Birgit Schultes, Ph.D. will become the Company&#8217;s Executive Vice President and CSO, effective as of January&#160;13, 2025. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Retirement Agreement, Dr.&#160;Sepp-Lorenzino will receive a revised base salary of $384,000 during the remainder of her employment with the Company and will be eligible for incentive compensation for 2024 consistent with the terms of her existing Employment Agreement but will not be eligible for a bonus or other incentive compensation for 2025. Dr.&#160;Sepp-Lorenzino will not be eligible for any severance pay or employee benefits following the ending of her employment unless there is a Change in Control (as defined in her existing Employment Agreement) and Dr.&#160;Sepp-Lorenzino&#8217;s employment is terminated following such Change in Control and before the anticipated retirement date, in which case she will be eligible for accelerated vesting of her outstanding equity awards consistent with her Employment Agreement, continued payment of her revised base salary through December&#160;31, 2025, and continued payment of the monthly employer contribution for health insurance through the earlier of December&#160;31, 2025 or the end of her COBRA health continuation period. Upon her retirement, subject to the terms of the Retirement Agreement, Dr.&#160;Sepp-Lorenzino will be eligible for the equity treatment set forth in the Company&#8217;s Amended and Restated Retirement Policy for Equity Awards (the &#8220;Retirement Policy&#8221;) , a copy of which was filed as Exhibit 10.30 to the Company&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K</span> (File <span style="white-space:nowrap">No.&#160;001-37766)</span> filed with the Securities and Exchange Commission on February&#160;23, 2023. The equity treatment set forth in the Retirement Policy includes the following with respect to all outstanding equity awards granted to Dr.&#160;Sepp-Lorenzino after July&#160;1, 2022, subject to the terms and conditions of the Retirement Policy: (i)&#160;continued vesting of stock options on the original vesting dates for such stock options, (ii)&#160;the ability to exercise vested stock options until the earlier of December&#160;31, 2030 and the original expiration date of the stock option, (iii)&#160;vesting of all unvested time-based restricted stock unit awards on December&#160;31, 2025, and (iv)&#160;continued eligibility to earn a pro rata portion of any outstanding performance-based equity awards at the end of the performance period based on actual achievement of the applicable performance metrics. In accordance with the Retirement Policy, Dr.&#160;Sepp-Lorenzino will not be eligible to receive any additional equity awards during 2025. The Retirement Agreement is otherwise materially consistent with the terms of Dr.&#160;Sepp-Lorenzino&#8217;s Employment Agreement, which is substantially similar to the form of employment agreement filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-37766)</span> filed with the Securities and Exchange Commission on April&#160;17, 2018, and the Company&#8217;s Retirement Policy. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;7.01 Regulation FD Disclosure. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;9, 2025, the Company issued a press release titled &#8220;Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran <span style="white-space:nowrap">(nex-z),&#8221;</span> a copy of which is attached hereto as Exhibit 99.1. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The information under this Item 7.01, including Exhibit 99.1 hereto, are being furnished herewith and shall not be deemed &#8220;filed&#8221; for the purposes of Section&#160;18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;8.01. Other Events. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;9, 2025, the Company announced its strategic priorities to focus on key value drivers and anticipated milestones for 2025. </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:3%;vertical-align:top" align="left"><span style="font-weight:bold">&#8226;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;font-weight:bold;text-align:left">Strategic Reorganization Focused on Key Value Drivers: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Company prioritized resources to focus on NTLA-2002 and nexiguran ziclumeran <span style="white-space:nowrap">(&#8220;nex-z&#8221;).</span> As part of this prioritization, the Company discontinued development of NTLA-3001 for the treatment of <span style="white-space:nowrap">alpha-1</span> antitrypsin deficiency-associated lung disease, as well as discontinuing select research-stage programs. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Over the course of 2025, the strategic reorganization will result in a net workforce reduction of approximately 27%. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Company expects to incur charges of approximately $8&#160;million associated with the reorganization, which is anticipated to be incurred in the first quarter of 2025. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Intellia ended the fourth quarter of 2024 with approximately $862&#160;million in cash, cash equivalents and investments. The combination of its cash balance and the anticipated cost savings are expected to provide the Company with cash runway into the first half of 2027. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:3%;vertical-align:top" align="left"><span style="font-weight:bold">&#8226;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;font-weight:bold;text-align:left">NTLA-2002 for Hereditary Angioedema (HAE):</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Patients are undergoing screening in the pivotal Phase 3 HAELO study for NTLA-2002 for HAE. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Presented clinical data, in October at the 2024 American College of Allergy, Asthma&#160;&amp; Immunology (ACAAI) Scientific Meeting, from the Phase 2 study that demonstrated the potential of NTLA-2002 to end chronic, prophylaxis treatment and provide freedom from attacks following a <span style="white-space:nowrap">one-time</span> infusion. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:3%;vertical-align:top" align="left"><span style="font-weight:bold">&#8226;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;font-weight:bold;text-align:left"><span style="white-space:nowrap">Nex-z</span> for Transthyretin (ATTR) Amyloidosis:</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Strong enrollment and momentum continue in the Phase 3 MAGNITUDE study of <span style="white-space:nowrap">nex-z</span> in patients with ATTR amyloidosis with cardiomyopathy <span style="white-space:nowrap">(ATTR-CM),</span> tracking ahead of the Company&#8217;s target enrollment projections. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Actively enrolling patients in the Phase 3 <span style="white-space:nowrap">MAGNITUDE-2</span> study of <span style="white-space:nowrap">nex-z</span> in patients with hereditary ATTR amyloidosis with polyneuropathy <span style="white-space:nowrap">(ATTRv-PN).</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Presented first clinical evidence, in November at the 2024 American Heart Association (AHA) Scientific Sessions, that consistent, rapid, deep and durable reductions in serum TTR achieved after a <span style="white-space:nowrap">one-time</span> treatment of <span style="white-space:nowrap">nex-z</span> may halt, and potentially reverse, disease progression. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:3%;vertical-align:top" align="left"><span style="font-weight:bold">&#8226;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;font-weight:bold;text-align:left">Corporate Update: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Laura Sepp-Lorenzino, Ph.D., the Company&#8217;s Executive Vice President and Chief Scientific Officer has announced her retirement effective December&#160;31, 2025. Dr.&#160;Sepp-Lorenzino will transition from her role as CSO and continue as a Senior Scientific Advisor for the remainder of the year. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Company also announced that Birgit Schultes, Ph.D., who has been leading the Company&#8217;s research and early development efforts in immunology and cell therapy since 2017, will be promoted to Executive Vice President and Chief Scientific Officer, effective January&#160;13, 2025. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:3%;vertical-align:top" align="left"><span style="font-weight:bold">&#8226;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;font-weight:bold;text-align:left">Strategic Priorities and Anticipated 2025 Milestones: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Intellia&#8217;s strategic priorities reflect the Company&#8217;s ongoing evolution from a late-stage development company to a commercial-ready organization by the end of 2026. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left"><span style="font-weight:bold">1.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold">Drive focused clinical execution to complete or accelerate enrollment in the pivotal studies of NTLA-2002 and <span style="white-space:nowrap">nex-z</span></span> </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">NTLA-2002 for HAE</span><span style="font-weight:bold">:</span> </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:18%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Dose the first patient in the pivotal Phase 3 HAELO trial in 1Q25 </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:18%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Complete HAELO enrollment in second half of 2025. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:18%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Present longer-term data from the Phase 1/2 study &#8211; data will include patients in the Phase 2 portion who initially received a 25 mg dose or placebo and were subsequently given the 50 mg dose of NTLA-2002 selected for the Phase 3 study. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline"><span style="white-space:nowrap">Nex-z</span> for ATTR amyloidosis</span>: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:18%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Dose the first patient in the pivotal Phase 3 <span style="white-space:nowrap">MAGNITUDE-2</span> trial for <span style="white-space:nowrap">ATTRv-PN</span> in 1Q25. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:18%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Enroll at least 550 patients across the MAGNITUDE trial for <span style="white-space:nowrap">ATTR-CM</span> by <span style="white-space:nowrap">year-end.</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:18%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Present longer-term data from both <span style="white-space:nowrap">ATTR-CM</span> and <span style="white-space:nowrap">ATTRv-PN</span> patients in the Phase 1 study &#8211; data will include updated measures of clinical efficacy and safety. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left"><span style="font-weight:bold">2.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold">Advance commercial readiness by implementing core commercialization and medical capabilities for initial launch in the U.S.</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:15%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Complete buildout of the commercial leadership team by second half of 2025. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:15%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Expand the reach of medical education activities in HAE and ATTR amyloidosis in partnership with key medical societies and patient organizations. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:15%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Initiate <span style="white-space:nowrap">pre-approval</span> information exchange to allow payers to begin planning for potential coverage and formulary decisions. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Forward Looking Statements. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report on&#160;Form <span style="white-space:nowrap">8-K</span> and&#160;certain of the materials furnished or filed herewith contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;target&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These forward-looking statements include, but are not limited to, express or implied statements regarding the Company&#8217;s beliefs and expectations regarding: ability to successfully develop and commercialize nexiguran ziclumeran <span style="white-space:nowrap">(&#8220;nex-z&#8221;),</span> formerly known as NTLA-2001, for the treatment of transthyretin (&#8220;ATTR&#8221;) amyloidosis and NTLA-2002 for the treatment of hereditary angioedema (&#8220;HAE&#8221;) to address the significant unmet needs of patients and prescribers in HAE and ATTR; its ability to achieve near-term clinical milestones, including dosing the first patient in the Phase 3 HAELO trial in the first quarter of 2025, completing enrollment in the Phase 3 HAELO trial in the second half of 2025, dosing the first patient in the Phase 3 <span style="white-space:nowrap">MAGNITUDE-2</span> trial for hereditary ATTR with polyneuropathy <span style="white-space:nowrap">(&#8220;ATTRv-PN&#8221;)</span> in the first quarter of 2025, enroll at least 550 patients across the Phase 3 MAGNITUDE trial for ATTR with cardiomyopathy <span style="white-space:nowrap">(&#8220;ATTR-CM&#8221;)</span> by <span style="white-space:nowrap">year-end,</span> and the expected timing of data releases from its clinical trials of <span style="white-space:nowrap">nex-z</span> and NTLA-2002, including longer-term data from the Phase 1/2 study of NTLA-2002, including data from patients that previously received the 25 mg dose or placebo and were subsequently given the 50 mg dose, and longer-term data from the Phase 1 study of <span style="white-space:nowrap">nex-z,</span> including updated measure of clinical efficacy and safety; its ability to prepare for commercial launch, including completing buildout of the commercial leadership team in the first half of 2025, expanding the reach of medical education activities in HAE and ATTR amyloidosis in 2025, and initiating, in 2025, <span style="white-space:nowrap">pre-approval</span> information exchange to allow payers to begin planning for coverage and formulary decisions; its interactions with regulatory authorities, including the potential submission of a biologics license application for NTLA-2002 for the treatment of HAE in the second half of 2026; its ability to optimize the impact of its collaborations on its development programs, including its collaboration with Regeneron Pharmaceuticals, Inc. and their <span style="white-space:nowrap">co-development</span> program for ATTR amyloidosis, and to advance additional development candidates; and its expectations regarding its uses of capital, expenses and ability to fund operations into the first half of 2027. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any forward-looking statements in this Current Report on Form <span style="white-space:nowrap">8-K</span> and certain materials furnished or filed herewith are based on management&#8217;s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellia&#8217;s ability to protect and maintain its intellectual property position; risks related to Intellia&#8217;s relationship with third parties, including its contract manufacturers, licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; uncertainties related to the authorization, initiation and conduct of preclinical and clinical studies and other development requirements for its product candidates, including uncertainties related to regulatory approvals to conduct clinical trials; risks related to the ability to develop and commercialize any one or more of Intellia&#8217;s product candidates successfully; risks related to the results of preclinical studies or clinical studies not being predictive of future results in connection with future studies; the risk that clinical study results will not be positive; risks related to the development and advancement of novel platform capabilities, such as DNA writing technology and gene editing in tissues outside the liver; risks related to Intellia&#8217;s future financial condition and its ability to fund its operations; and risks related to Intellia&#8217;s collaborations with Regeneron Pharmaceuticals, Inc. or its other collaborations not continuing or not being successful. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause the Company&#8217;s actual results to differ from those contained in the forward-looking statements, see the section entitled &#8220;Risk Factors&#8221; in the Company&#8217;s most recent quarterly report on Form <span style="white-space:nowrap">10-Q,</span> as well as discussions of potential risks, uncertainties, and other important factors in the Company&#8217;s other filings with the Securities and Exchange Commission. All information in this Current Report on Form <span style="white-space:nowrap">8-K</span> is as of the Date of Report indicated above, and the Company undertakes no duty to update this information unless required by law. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;9.01 Financial Statements and Exhibits. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap">Exhibit<br/>No.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d906527dex991.htm">Press release dated January&#160;9, 2025.</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3">Intellia Therapeutics, Inc.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: January&#160;10, 2025</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John M. Leonard</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name: John M. Leonard</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title: Chief Executive Officer and President</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d906527dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g906527g0110034504806.jpg" ALT="LOGO" STYLE="width:6.57569in;height:1.15556in;">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Intellia Therapeutics Announces Anticipated 2025 Milestones and </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Priority programs &#150; NTLA-2002 for hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) for
transthyretin (ATTR) amyloidosis &#150; set foundation for significant, near-term value creation</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase 3 HAELO study evaluating NTLA-2002 for HAE to complete enrollment in the second half of 2025; Company
plans to submit a Biologics License Application in the second half of 2026</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>More than 550 patients expected to be enrolled by year end within the ongoing MAGNITUDE study for nex-z in <FONT
STYLE="white-space:nowrap">ATTR-CM</FONT> &#150; the program remains ahead of internal enrollment estimates</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Pipeline priorities result in NTLA-3001 discontinuation and select, research-focused investment </I>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Anticipated cost savings, including a net workforce reduction of approximately 27% in 2025, support company
operations into 1H 2027 and through anticipated, first commercial launch in the U.S.</I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CAMBRIDGE, Mass., Jan. 9, 2025 &#150; Intellia
Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced its strategic priorities and key anticipated 2025 milestones that support the
Company&#146;s mission to transform the lives of patients and bring forth a new era in medicine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We have made significant progress and built strong
momentum in 2024 with three actively enrolling, Phase 3, pivotal studies. Our early clinical data for both NTLA-2002 and nex-z support novel, highly differentiated product profiles that directly address the significant unmet needs of patients and
prescribers in HAE and ATTR,&#148; said John Leonard, M.D., President and Chief Executive Officer of Intellia. &#147;We understand the significant potential of our late-stage programs, and within a challenging market environment, have made a
difficult decision to focus our resources predominantly on NTLA-2002 and nex-z where we have the greatest opportunity to create significant, near-term value.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Pipeline Advancement and Corporate Updates </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Strategic Reorganization Focused on Key Value Drivers:</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The pipeline prioritization is intended to focus resources on high value programs&#151;NTLA-2002 and
nex-z&#151;to ensure efficient execution, achieve near-term clinical milestones, and prepare Intellia for commercial launch. As part of this prioritization, the Company discontinued development of NTLA-3001 for the treatment of <FONT
STYLE="white-space:nowrap">alpha-1</FONT> antitrypsin deficiency-associated lung disease and select research-stage programs. Over the course of 2025, the strategic reorganization will result in a net workforce reduction of approximately 27%.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Page 1 of 5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">intelliatx.com</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Company expects to incur charges of approximately $8&nbsp;million associated with the reorganization, which
are anticipated to be incurred in the first quarter of 2025. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Intellia ended the fourth quarter of 2024 with approximately $862&nbsp;million in cash, cash equivalents and
investments. The combination of its cash balance and the anticipated cost savings are expected to provide the Company with cash runway into the first half of 2027. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Laura Sepp-Lorenzino, Ph.D., Intellia&#146;s Chief Scientific Officer, has announced her retirement effective
December&nbsp;31, 2025 after more than 30 years of service in the biopharmaceutical industry and academia. Dr.&nbsp;Sepp-Lorenzino will transition from her role as CSO and continue as a Senior Scientific Advisor for the remainder of the year.
&#147;I would like to thank Laura for her service to Intellia. She has been a tireless innovator and advocate for the promise of gene editing, and we look forward to continuing the work and vision she championed,&#148; said John Leonard M.D.,
President and Chief Executive Officer of Intellia. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Company also announced that Birgit Schultes, Ph.D., who has been leading Immunology and Cell Therapy since
2017, will be promoted to Executive Vice President and Chief Scientific Officer, effective January&nbsp;13, 2025. Dr.&nbsp;Schultes has over 20 years of experience in drug development and biotechnology, including the clinical development of cell
therapies and complex biologic products. Dr.&nbsp;Schultes received her M.S. in biology and Ph.D. in immunology from the University of Bonn, Germany, and completed the Advanced Management Development Program at the Boston University Questrom School
of Business. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>NTLA-2002 for Hereditary Angioedema (HAE):</B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Patients are actively enrolling in the pivotal Phase 3 HAELO study. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Presented clinical data, in October at the 2024 American College of Allergy, Asthma&nbsp;&amp; Immunology (ACAAI)
Scientific Meeting, from the Phase 2 study that demonstrated the potential of NTLA-2002 to end chronic, prophylaxis treatment and provide freedom from attacks following a <FONT STYLE="white-space:nowrap">one-time</FONT> infusion.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Nex-z for Transthyretin (ATTR) Amyloidosis:</B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Strong enrollment and momentum continue in the Phase 3 MAGNITUDE study in patients with ATTR amyloidosis with
cardiomyopathy <FONT STYLE="white-space:nowrap">(ATTR-CM),</FONT> tracking ahead of the Company&#146;s target enrollment projections. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Page 2 of 5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">intelliatx.com</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Patients with hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN) are actively screening in the Phase 3 <FONT
STYLE="white-space:nowrap">MAGNITUDE-2</FONT> study. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Presented first clinical evidence, in November at the 2024 American Heart Association (AHA) Scientific Sessions,
that consistent, rapid, deep and durable reductions in serum TTR achieved after a <FONT STYLE="white-space:nowrap">one-time</FONT> treatment of nex-z may halt, and potentially reverse, disease progression. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Strategic Priorities and Anticipated 2025 Milestones </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intellia&#146;s strategic priorities reflect the Company&#146;s ongoing evolution from a late-stage development company to a commercial-ready organization by
the end of 2026. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Drive focused clinical execution to complete or accelerate enrollment in the pivotal studies of NTLA-2002 and nex-z </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>NTLA-2002 for HAE</U>: </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Dose the first patient in the pivotal Phase 3 HAELO trial in 1Q25. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Complete HAELO enrollment in second half of 2025. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Present longer-term data from the Phase 1/2 study &#150; data will include patients in the Phase 2 portion who
initially received a 25 mg dose or placebo and were subsequently given the 50 mg dose of NTLA-2002 selected for the Phase 3 study. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B><U>Nex-z for ATTR amyloidosis</U>: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Dose the first patient in the pivotal Phase 3 <FONT STYLE="white-space:nowrap">MAGNITUDE-2</FONT> trial for
ATTRv-PN in 1Q25. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Enroll at least 550 patients cumulatively within the MAGNITUDE trial for
<FONT STYLE="white-space:nowrap">ATTR-CM.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Present longer-term data from both <FONT STYLE="white-space:nowrap">ATTR-CM</FONT> and ATTRv-PN patients in the
Phase 1 study &#150; data will include updated measures of clinical efficacy and safety. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Advance commercial readiness by
implementing core commercialization and medical capabilities for initial launch in the U.S. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>Complete buildout of the commercial leadership team by second half of 2025. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>Expand the reach of medical education activities in HAE and ATTR amyloidosis in partnership with key
medical societies and patient organizations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>Initiate <FONT STYLE="white-space:nowrap">pre-approval</FONT> information exchange to allow payers to
begin planning for coverage and formulary decisions. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Page 3 of 5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">intelliatx.com</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Presentation at the 43<SUP STYLE="font-size:75%; vertical-align:top">rd</SUP> Annual J.P. Morgan
Healthcare Conference </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">John Leonard, M.D., President and Chief Executive Officer of Intellia, will present a company overview at the 43<SUP
STYLE="font-size:75%; vertical-align:top">rd</SUP> Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January&nbsp;13, at 8:15 a.m. PT (11:15 a.m. ET). A live webcast will be available through the Events and Presentations page of
the Investors&nbsp;&amp; Media section on Intellia&#146;s website, <U>www.intelliatx.com</U>. A replay of the webcast will be available on Intellia&#146;s website for a limited time following the conference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Intellia Therapeutics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intellia Therapeutics, Inc.
(NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia&#146;s deep scientific, technical and clinical
development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and
delivery technologies. Learn more at&nbsp;intelliatx.com and follow us @intelliatx. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains &#147;forward-looking statements&#148; of&nbsp;Intellia Therapeutics, Inc.&nbsp;(&#147;Intellia&#148; or the &#147;Company&#148;)
within the meaning of the Private Securities Litigation Reform Act of 1995.&nbsp;These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia&#146;s beliefs and expectations concerning: its
ability to successfully develop and commercialize nexiguran ziclumeran <FONT STYLE="white-space:nowrap">(&#147;nex-z&#148;),</FONT> formerly known as NTLA-2001, for the treatment of transthyretin (&#147;ATTR&#148;) amyloidosis and NTLA-2002 for the
treatment of hereditary angioedema (&#147;HAE&#148;) to address the significant unmet needs of patients and prescribers in HAE and ATTR; its ability to achieve near-term clinical milestones, including dosing the first patient in the Phase 3 HAELO
trial in the first quarter of 2025, completing enrollment in the the Phase 3 HAELO trial in the second half of 2025, dosing the first patient in the Phase 3 <FONT STYLE="white-space:nowrap">MAGNITUDE-2</FONT> trial for hereditary ATTR with
polyneuropathy <FONT STYLE="white-space:nowrap">(&#147;ATTRv-PN&#148;)</FONT> in the first quarter of 2025, enroll at least 550 patients across the Phase 3 MAGNITUDE trial for ATTR with cardiomyopathy
<FONT STYLE="white-space:nowrap">(&#147;ATTR-CM&#148;)</FONT> by <FONT STYLE="white-space:nowrap">year-end,</FONT> and the expected timing of data releases from its clinical trials of <FONT STYLE="white-space:nowrap">nex-z</FONT> and NTLA-2002,
including longer-term data from the Phase 1/2 study of NTLA-2002, including data from patients that previously received the 25 mg dose or placebo and were subsequently given the 50 mg dose, and longer-term data from the Phase 1 study of <FONT
STYLE="white-space:nowrap">nex-z,</FONT> including updated measure of clinical efficacy and safety; its ability to prepare for commercial launch, including completing buildout of the commercial leadership team in the first half of 2025, expanding
the reach of medical education activities in HAE and ATTR amyloidosis in 2025, and initiating <FONT STYLE="white-space:nowrap">pre-approval</FONT> information exchange to allow payers to begin planning for potential coverage and formulary decisions
in 2025; its interactions with regulatory authorities, including the potential submission of a biologics license application for NTLA-2002 for the treatment of HAE in the second half of 2026; its ability to optimize the impact of its collaborations
on its development programs, including its collaboration with Regeneron Pharmaceuticals, Inc. and their <FONT STYLE="white-space:nowrap">co-development</FONT> program for ATTR amyloidosis, and to advance additional development candidates; and its
expectations regarding its uses of capital, expenses, and ability to fund operations into the first half of 2027. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Page 4 of 5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">intelliatx.com</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any forward-looking statements in this press release are based on management&#146;s current expectations and
beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements.&nbsp;These risks and
uncertainties include, but are not limited to: risks related to Intellia&#146;s ability to protect and maintain its intellectual property position; risks related to Intellia&#146;s relationship with third parties, including its contract
manufacturers, licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; uncertainties related to the authorization, initiation and conduct of preclinical and clinical
studies and other development requirements for its product candidates, including uncertainties related to regulatory approvals to conduct clinical trials; risks related to the ability to develop and commercialize any one or more of Intellia&#146;s
product candidates successfully; risks related to the results of preclinical studies or clinical studies not being predictive of future results in connection with future studies; the risk that clinical study results will not be positive; risks
related to the development and advancement of novel platform capabilities, such as DNA writing technology and gene editing in tissues outside the liver; risks related to Intellia&#146;s future financial condition and its ability to fund its
operations; and risks related to Intellia&#146;s collaborations with Regeneron Pharmaceuticals, Inc. or its other collaborations not continuing or not being successful.&nbsp;For a discussion of these and other risks and uncertainties, and other
important factors, any of which could cause Intellia&#146;s actual results to differ from those contained in the forward-looking statements, see the section entitled &#147;Risk Factors&#148; in Intellia&#146;s most recent quarterly report on Form <FONT
STYLE="white-space:nowrap">10-Q,</FONT> as well as discussions of potential risks, uncertainties, and other important factors in Intellia&#146;s other filings with the&nbsp;Securities and Exchange Commission.&nbsp;All information in this press
release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellia Contacts:
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investors: </B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Precision AQ for Intellia
Therapeutics </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>intelliatx@precisionaq.com </U></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media:
</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Matt Crenson </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ten Bridge Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>media@intelliatx.com</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>mcrenson@tenbridgecommunications.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"># #
# </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Page 5 of 5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">intelliatx.com</TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ntla-20250109.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 1/10/2025 9:32:44 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2024"
  xmlns:ntla="http://intelliatx.com/20250109"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://intelliatx.com/20250109"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" namespace="http://xbrl.sec.gov/naics/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ntla-20250109_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ntla-20250109_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://intelliatx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>ntla-20250109_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 1/10/2025 9:32:44 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>ntla-20250109_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 1/10/2025 9:32:45 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://intelliatx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="ntla-20250109.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://intelliatx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g906527g0110034504806.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g906527g0110034504806.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !M FX# 2(  A$! Q$!_\0
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M@ HHHH **** *EWJ=G8NJW,XC9AD @\U8BE2>))8VW(XW*?45R/C+_C\M_\
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M3/$<MYJ,-LZ6K"9I5Q#*2\6PD9=>P..N>I%6=:UF33;VSMTDM8A/'(YDN6(
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU6&]GNW=8"QAB"*H4D8.3U/!-:-%%"202DY6OT"BBBF2%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>E45C^'?^15L?^O<4WPS_P @Z3_KLW\ZVB[QN<52/)-P[&U17SAJO_(6O/\
MKL_\S7IWP^_Y$J]_WW_E7+1Q7M)\ECU<9E?U:A[;GO\ +_@GH-%8OA7_ ) <
M?^^W\ZSO&?\ RZ_C79;6QXSEI<ZNBN7\-_\ ( O/^!?^@UI>&_\ D"0_4_SH
M:L-.YK45YQK?_(:N_P#KH:Z;PA_R"Y/^NA_E3<;*Y*E=V.AHKS35O^0O=_\
M75OYUZ%I_P#R#K?_ *YK_*AJPXRNRS16!XN_Y Z_]=E_D:V8?^/./_<'\J5M
M!WUL345YE9?\A2W_ .NR_P#H5;7C+_C^M_\ KE_4U7+K8GGTN=G169X?_P"0
M':_[O]:Y;PG_ ,C]XF_ZZ?\ LQK&<^627<Z:-'VD)SO\*O\ C8[RBO /&'_(
MWZI_UW:NC^%'_(>O?^O7_P!F6N:.+YJG)8].KE'L\/[?GZ7M;_@FMJMO.VK7
MA6&0@S-@A3ZUVVAJRZ+:JP((3D$>YK0HKN<KH\11L[E+6%+:/=JH))B. !4'
MAU630K964JP#9!&#]XUJ44KZ6';6Y%<@FUE _N'^5>9BUN,_ZB7_ +X->HT4
MU*PI1N<WK<<C:7I@5&)#ID =/EKI***5QI'*^,(I)&M/+C9L!L[1GTIR12?\
M('=Q^6V\P2 +CGOVKJ**4M8\HX>Y-3/F_P#LV^_Y\KG_ +]-_A78?#:SNH/%
M&^6VFC7RFY="!7L%%<4,$H24K['MU\ZE6I2I\EK^9PWB>"9]99DB=AL'(4FM
MC48W/A.% C%OW?R@<]:Z&BN_F/"Y=R.WXMH@?[@_E7->+XI)/LWEQLV,YVC-
M=3123L[C:NK'$^%H)8]7W/$ZC8>2I%6-0BE/B^%Q&Y7<OS!3BNNHI\VMR>72
MP5PUI!,/%2.8G"^>3NVG%=S123L4U<****0SF?&$<DD-KY:,V&.=HS3_  ]'
M(F@7*LC*QW8!&#TKHZ*J^EB>76YE>'59-&B5U*G)X(QWK5HHJ6-:(H:VC2:'
M?(BEF:%@%49)XK$\,^&=+71;"XN-+B%YY:LQD3Y@WN#WKJJ*S=-.7,S>-><*
M;IQTN[E'649]#OD12S&W<*JC)/RFN%C\."RT/2=:M]-\RZMPIN;9HLF0'J=I
M_B%>D44JE%3=V:4,5*C'ECW_ .!8IW$@N='F>-6_>0,54J0>5Z8]:XKPW?6&
MGZ9;6]WH%XUXC',OV#/.[@[CS7H-%$Z;E)2N*G74(.#6C\[%349;R+39I=/B
M26Z5=T<<G1O;\JX>_P ZU>Z;)I^AWEEJR3JT\S0&(*O\66_B_P ^M>AT45*?
M/U"AB/9:I:_UOW14U%[V+3II+"*.6Z5<HDG1CW%</?[M:O=,DT_1+RQU9)U>
M>=H#$J*/O9;^+\?ZUZ'114I<_4*&(]CJEK_6_=!VK/UU&D\/:FB*6=K24*JC
M))V'@5H45HU=6,(RY9*78\X7PXMAHFC:W;:8);FV"F[MFBW&53P3M/\ $/\
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#C__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46276715058704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 09, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001652130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan.  09,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INTELLIA THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">36-4785571<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">40 Erie Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(857)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">285-6200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock (Par Value $0.0001)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NTLA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( ,H[*EH'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #*.RI:-[L+G>T    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)O)VE1,'1S43PI""XHWD(RNQMLTI",M/OVMG&WB^@#>,S,GV^^
M@>E,E&9(^)R&B(D<YJO)]R%+$S?L0!0E0#8']#K7<R+,S=V0O*;YF?80M?G0
M>X2&\QOP2-IJTK  J[@2F>JLD2:AIB&=\-:L^/B9^@*S!K!'CX$RB%H 4\O$
M>)SZ#BZ !4:8?/XNH%V)I?HGMG2 G9)3=FMJ',=Z;$MNWD' V]/C2UFW<B&3
M#@;G7]E).D;<L//DU_;N?OO 5,.;ZXJ+2O"M:&3+I;A]7UQ_^%V$_6#=SOUC
MX[.@ZN#77:@O4$L#!!0    ( ,H[*EJ97)PC$ 8  )PG   3    >&PO=&AE
M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?
MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@
MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<
MX%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C 1-7
M02:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP
M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=
MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP
M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,
M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I
MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E
M,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ
MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A
M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\
M'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:
MP4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:
M<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY 1
MOQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >C
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?
MP.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>
M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3
M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'
M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\
M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^
M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'
M<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!
M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0
M!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%(1=R
MX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+
MPWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M7>EYIK=WDWM)J'7N0;#W\!J-'<V/'[?\ 5!+ P04    " #*.RI:)!Z;HJT
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M2P$"% ,4    " #*.RI:!T%-8H$   "Q    $               @ $
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( ,H[*EHWNPN=[0   "L"   1
M              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M ,H[*EJ97)PC$ 8  )PG   3              "  <L!  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ RCLJ6@Z-8>=G!   +!$  !@
M     ("!# @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M ,H[*EJ?H!OPL0(  .(,   -              "  :D,  !X;"]S='EL97,N
M>&UL4$L! A0#%     @ RCLJ6I>*NQS     $P(   L              ( !
MA0\  %]R96QS+RYR96QS4$L! A0#%     @ RCLJ6APX9>H_ 0  / (   \
M             ( !;A   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( ,H[
M*EHD'INBK0   /@!   :              "  =H1  !X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( ,H[*EIED'F2&0$  ,\#   3
M          "  ;\2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D
*/@(   D4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d906527d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://intelliatx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d906527d8k.htm">d906527d8k.htm</File>
    <File>ntla-20250109.xsd</File>
    <File>ntla-20250109_lab.xml</File>
    <File>ntla-20250109_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d906527d8k.htm": {
   "nsprefix": "ntla",
   "nsuri": "http://intelliatx.com/20250109",
   "dts": {
    "inline": {
     "local": [
      "d906527d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "ntla-20250109.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ntla-20250109_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ntla-20250109_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://intelliatx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-01-09_to_2025-01-09",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d906527d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-01-09_to_2025-01-09",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d906527d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://intelliatx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://intelliatx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://intelliatx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://intelliatx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://intelliatx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://intelliatx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://intelliatx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://intelliatx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://intelliatx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://intelliatx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://intelliatx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://intelliatx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://intelliatx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://intelliatx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://intelliatx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://intelliatx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://intelliatx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://intelliatx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://intelliatx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://intelliatx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://intelliatx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://intelliatx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://intelliatx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-25-004080-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-004080-xbrl.zip
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M)GNMO<N./UVSSF:K"0\^Q2>PPM_Y^'L#O-@!: ?#+\#(@)OYKX>\>]\3\N:
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M"<4BP8E08O;#._'Z*#(=MT9_=[T$R-Z91B%8/N%*CCWPH2]PJX-4!EX\ K@
M 0LM]L%F&>&A(Q+T!2C& $V7&4?JG,DUQ2_X],#ST0A??.3VHB/3V8,>$H6Q
M(#33>LB"KR^\)M)J]A;4U^N(\GRL,)$8Y*M U9[Z58!+5DV(9M8]Z(4L3OO_
M >@:X@"!T/=\!06""_#K6$&_#D@E-7IY-G9Y608/?  5-ZO:A-B+FJ@.-)H9
MH*&-,AO"=19.7R/4T2<D(DHR!MF"06X8TI31,,P=J]QCI[B(.'6 ./0Z-)P>
MI?6]-U!'MH$IQL#H>G$<.AX!CXCX] '9IF0G7@P$ $P1=N[=$;1>726YG"W2
M,QYN:0#X;00V")[EGUD(&6HN<+Z2!!!PI  X> ,4E#%S /[H)T%K8RCY6(ER
MSM#\2< ,PF.#OU,G ?0 C,'XM03TWC'JYC1NF*EM)&0 @0UWYU)HA4,%OBF#
MJ5KXH$(ATP!T:(R5"W4T',A!4$S\ >X!=KW[^M+@C'2$0-&7.GWB]J@K#4 \
MAF7H$H.O!E;QC"S5BVJTC>DPX"BP3H:;.O99"96_)1@6!"/3$"FIJ)YU=G]D
M(" EH8.2[]E4<4)/Q9EV=^^1V@$X@*<CAXJ7E/6]HK:'+#\6, /6.J1]$H_*
M%X<(!'H"+KP!:@_1BX,$5$<@P4D A)6X-&=I]&)UG-L9PA#5H0("9K?UKM8W
M"72HY:22KO_43(B)V>HB/B$=Y5$XX#KN0_D5-N8("^@$G#XQ7M2[$E![8'*R
MWT6B5,7'MY!-1"NFS6035AT_GD.=((I/)*@O#O%/*?!09$$$ (90!#>=5QRG
MXR@WD3@@FF6$C(%X7 \OX8M@P.^Y'^N)&5Y1XABD/.):43/1W('V#68(;)V
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M,Q_A"=6NDS-]:-O&_D4;1N_A^/+GZYX95B^,6Q=!3?9;% 9ZN^9XZF4+/Z/
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MLSN+V1=/<NPL[%!=(&_1SF9K[_WXDJ1=@K KG%#5FNA2V R6XYP*W>J=SJQ
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MDLIHRA&^JH":$7JES+::%EXI7J)*S@*P92*1C&DG<7T+\Q7)3,+2XJJV/':
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MKC)6)MZ2AA?=&W?.-7+T.S-,Z\B6RT'*&"_IT.;F3>N7(F\&W?Y*]R8"AS[
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M(YQXY!]02P$"% ,4    " #*.RI:&X!'D7(E   E\0  #@
M@ $     9#DP-C4R-V0X:RYH=&U02P$"% ,4    " #*.RI:&/&CD#89   3
ME   $0              @ &>)0  9#DP-C4R-V1E>#DY,2YH=&U02P$"% ,4
M    " #*.RI:IX-433X#  !&"P  $0              @ $#/P  ;G1L82TR
M,#(U,#$P.2YX<V102P$"% ,4    " #*.RI:2Z5&=WH&  "Y1@  %0
M        @ %P0@  ;G1L82TR,#(U,#$P.5]L86(N>&UL4$L! A0#%     @
MRCLJ6E&H>/?!!   .RP  !4              ( !'4D  &YT;&$M,C R-3 Q
@,#E?<')E+GAM;%!+!08     !0 % $ !   13@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>d906527d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ntla-20250109.xsd" xlink:type="simple"/>
    <context id="duration_2025-01-09_to_2025-01-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
        </entity>
        <period>
            <startDate>2025-01-09</startDate>
            <endDate>2025-01-09</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-553">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-01-09_to_2025-01-09"
      id="Hidden_dei_EntityCentralIndexKey">0001652130</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-564">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-565">2025-01-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-566">INTELLIA THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-567">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-568">001-37766</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-569">36-4785571</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-570">40 Erie Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-571">Suite 130</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-572">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-573">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-574">02139</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-575">(857)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-576">285-6200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-577">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-578">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-579">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-580">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-581">Common Stock (Par Value $0.0001)</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-582">NTLA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-583">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-584">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
